Get the Weekly Intelligence Brief — top committee picks every Sunday.
NASDAQ · STOCK

Insulet Corporation

PODD Healthcare Unknown Updated July 31, 2026
$165.32
52W $138.79 – $354.88
55/100
$11.45B
38.4
1.11
AI Committee Verdict
Watch
Conviction: High · 83% agreement · 6 analysts
+113.8%
-16.0%
7.09:1
High

Is PODD Bullish or Bearish?

Mixed. Innellis AI committee rates Insulet Corporation (PODD) Watch with a composite score of 55/100 , based on 6 analysts with 83% agreement. Last updated July 31, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +5.04 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -14.96 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

Some positive signals exist — news sentiment is positive (+0.25 across 4 articles, 14d) — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.

Bull & Bear Case

Bull Case
  • ROE of 17.4% shows genuine earnings power backing the valuation — Value
  • Revenue growing 31.9% YoY -- genuine top-line momentum — Growth
  • 4 consecutive earnings beats -- consistent execution — Growth
  • MACD histogram positive -- bullish momentum — Technical
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
  • News sentiment is positive (+0.25 across 4 articles, 14d) — News
Bear Case
  • P/E of 38.4 is moderate-to-rich — Value
  • Price-to-book of 13.2x prices in significant intangible value — Value
  • EPS declining -21.1% YoY despite any revenue growth — Growth
  • Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of July 31, 2026
Overall Committee Score
55/100
Agreement
83%
Analysts
6
Conviction
High
Sector Rank
Top 55%
of 93 Healthcare peers
Value Analyst neutral
48 / 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 17.4% shows genuine earnings power backing the valuation
− P/E of 38.4 is moderate-to-rich
Growth Analyst neutral
55 / 100 · High confidence
Moderate growth -- present but not remarkable
+ Revenue growing 31.9% YoY -- genuine top-line momentum
− EPS declining -21.1% YoY despite any revenue growth
Technical Analyst neutral
58 / 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
Macro Analyst neutral
58 / 100 · Moderate confidence
Macro backdrop is mixed or neutral -- not a strong tailwind or headwind either way
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst bullish
66 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.25 across 4 articles, 14d)
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2744.14)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 56.7 to 55.0.

Analyst-level changes:
  • Macro Analyst: stance bullish->neutral; score 65->58 (-8); +1 bullish signal(s).
  • News Analyst: +1 bullish signal(s).
  • Portfolio Manager: +2 bearish signal(s).
  • Value Analyst: +1 bearish signal(s).

Comparing 2026-07-30 to 2026-07-31 (1 day apart).

Technical Analysis

RSI (14)
54.1
Neutral
MACD Histogram
0.276
Bullish Momentum
Trend Direction
Sideways
Weekly: Downtrend
Market Structure
Lh Ll
Support
$138.81
Resistance
$353.41
Bollinger %B
0.68
Inside Bands
Price vs Moving Averages
EMA 9
$165.02 Above
EMA 21
$162.31 Above
EMA 50
$163.14 Above
EMA 200
$213.17 Below

Fundamental Analysis

Valuation
36
Growth
69
Profitability
1
Financial Health
94
Cash Flow
37
Valuation
P/E Ratio 38.4×
P/B Ratio 8.88×
PEG Ratio -1.54
Dividend Yield 0.00%
52W High $354.88
52W Low $138.79
Quality & Growth
ROE 16.3%
ROA 7.8%
Gross Margin 71.0%
Operating Margin 17.5%
Revenue Growth YoY
Debt / Equity 0.73
AI Fundamental Assessment
P/E ratio of 38.4 (rich relative to a 15-40x range); Price-to-book of 8.9x; PEG ratio of -1.5 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 0.2%; Return on assets of 0.1%; Net margin of 0.1%; Gross margin of 0.7%; Current ratio of 2.49 (healthy short-term liquidity); Debt-to-equity of 0.73; Free cash flow margin of 0.7% (thin cash generation); Free cash flow per share is positive (5.89); Most recent quarter beat estimates by 16.2%; 4 consecutive earnings beats; EPS growth decelerating (+25.0% -> -8.4% QoQ); Analyst estimates rising over recent quarters
Get the Full PODD Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →

Explore PODD Further

📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime